Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

62.40
-0.4600-0.73%
Post-market: 62.450.0487+0.08%19:59 EDT
Volume:15.87M
Turnover:998.92M
Market Cap:127.03B
PE:13.74
High:64.13
Open:63.28
Low:62.40
Close:62.86
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:1.11
T/O Rate:0.78%
Dividend:2.51
Dividend Rate:4.02%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.69
PE(LYR):18.03

Loading ...

U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions

Reuters
·
Sep 01

Oxford BioMedica Slides as Novartis, Bristol-Myers Squibb Pause CAR-T Autoimmune Trials

Reuters
·
Sep 01

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

Bristol-Myers Squibb Spokesperson - Implemented a Voluntary Pause to Review Clinical Data Across Our Zola-Cel Program

THOMSON REUTERS
·
Sep 01

Rpt: Bristol-Myers Squibb Also Pauses Similar Trials as a Precautionary Measure- WSJ

THOMSON REUTERS
·
Sep 01

Novartis Pauses Autoimmune Cell Therapy Studies After Deaths

Dow Jones
·
Sep 01

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Aug 31

Bristol Myers presents results for EXPLORER-LTE cohort of MAVA-LTE study

TIPRANKS
·
Aug 31

Procter & Gamble, Target, Canopy, Bristol, Oklo Insider Shock

TIPRANKS
·
Aug 29

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Sweden's Elicera Therapeutics Q2 Loss Widens

Reuters
·
Aug 28

Bristol-Myers Squibb Extends Deucravacitinib Program, Signaling Long-Term Autoimmune Ambitions

TIPRANKS
·
Aug 28

China's HBM Holdings H1 Revenue Rises on Progress on Mid-Late Clinical Stage Programs

Reuters
·
Aug 27

Top Bristol-Myers Squibb Executive Makes Notable Move With Recent Stock Sale

TIPRANKS
·
Aug 27

Bristol Myers Squibb SVP, Controller Phil M. Holzer Sells 500 Shares for $33,750

Reuters
·
Aug 27

Bloomsbury Ties Executive Share Awards to Long-Term Performance Targets

TIPRANKS
·
Aug 26

Bristol Myers Squibb Stock (BMY) Looks Healthier After Ditching Blood Cancer Partner

TIPRANKS
·
Aug 26

Bristol Myers Ends Blood Cancer Drug Deal with Cell Therapy Maker Cellares

Reuters
·
Aug 26

Confirm That We Have Ended Our Partnership with Cellares. - Bristol Myers Spokesperson

THOMSON REUTERS
·
Aug 25

Bristol Myers Spokesperson: Determined Cellares-Partnered Cell Shuttle System Could not Meet Necessary Requirements to Make Commercial Breyanzi

THOMSON REUTERS
·
Aug 25